Powered by Insilico’s proprietary Pharma.AI platform, the BBB (blood-brain barrier) penetrable molecule was designed as a potential treatment of various inflammation-related diseases, including gout ...
DOVER, Del., Feb. 2, 2026 /PRNewswire/ -- Mwyngil Therapeutics, a clinical-stage biopharmaceutical company focused on immunometabolic and neuroinflammatory diseases, today announced the initiation of ...
Artificial-intelligence-powered drug developer Insilico Medicine is set for a $10 million upfront payment from a fresh-faced Chinese biotech for half of the rights to a brain-penetrant NLRP3 inhibitor ...
A research team has uncovered a new mechanism that allows Mycobacterium tuberculosis (Mtb), the bacterium that causes tuberculosis (TB), to evade host immune defenses. New research from the Kennedy ...
Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of discovery efforts based on insights from BioAge’s platform, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results